AP-5346. Polymer-delivered platinum complex

Drugs of the Future

Volumn 29, Issue 6, 2004, Pages 561-565

  Rice, John R ^a   Howell, Stephen B ^b,c  

^a Access Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AP 5346; CARBOPLATIN; CYCLOHEXANE DERIVATIVE; DIAMINOCYCLOHEXANE; DRUG CARRIER; HYDROXYPROPYLMETHACRYLAMIDE; OXALIPLATIN; PLATINUM COMPLEX; POLYMER; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CAPILLARY PERMEABILITY; CLINICAL TRIAL; CYTOTOXICITY; DNA DRUG COMPLEX; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MACROMOLECULE; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; TUMOR;

EID: 3943108941     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.06.816764     Document Type: Article

References (14)

1. Kelland, L.R., Farrell, N.P. (Eds.). Platinum-Based Drugs in Cancer Chemotherapy. Humana Press, Totowa, 2000.
2. Pinedo, H.M., Schornagel, J.H. (Eds.). Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Plenum Press, New York, 1996.
3. Missett, J.L., Bleiberg, H., Sutherland, W., Bekradda, M., Cvitkovic, E. Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000, 35: 75-93.
4. Seymour, L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992, 9: 135-87.
5. Duncan, R. Polymer therapeutics for tumour specific delivery. Chem Ind (London) 1997, 262-4.
6. Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer therapy: Mechanisms of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986, 46: 6387-92.
7. Mukherjee, S., Ghosh, R.N., Maxfield, F.R. Endocytosis. Physiol Rev 1997, 77: 759-803.
8. Kopecek, J., Rejmanova, P., Strohalm, J., Ulbrich, K., Rihova, B., Chytry, V., Lloyd, J.B., Duncan, R. (Ceskoslovenska Akademie Ved; Carlton Medical Products Ltd.). Synthetic polymeric drugs. EP 0187547, JP 1986243026, JP 1995300428, US 5037883.
9. Brabec, V. Chemistry and structural biology of 1,2-interstrand adducts of cisplatin. In: Platinum-Based Drugs in Cancer Chemotherapy. L.R. Kelland and N.P. Farrell (Eds.), Humana Press, Totowa, 2000, 37-61.
10. Reynolds, T. Polymers help guide cancer drugs to tumor targets - and keep them there. J Natl Cancer Inst 1995, 87: 1582-4.
11. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., Maeda, H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998, 89: 307-14.
12. Duncan, R., Spreafico, F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin Pharmacokinet 1994, 27: 290-306.
13. Duncan, R. Drug-polymer conjugates: Potential for improved chemotherapy. Anticancer Drugs 1992, 3: 175-210.
14. Gianasi, E., Wasil, M., Evagorou, E.G., Keddle, A., Wilson, G., Duncan R. HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999, 35: 994-1002.